Two medicines, side by side
Abaloparatide vs baclofen
Abaloparatide is labeled for osteoporosis; baclofen for muscle spasms and spasticity. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of abaloparatide since 2017 and of baclofen since 1977. In FDA's classes, abaloparatide is a parathyroid hormone-related peptide analog and baclofen a gamma-aminobutyric acid-ergic agonist.
Check it at the source: the abaloparatide FDA label on DailyMed (effective August 11, 2026); the baclofen FDA label on DailyMed (effective August 12, 2024).
Highlights of the abaloparatide record
Abaloparatide (Tymlos) · label of August 11, 2026
Used for
From the label: indicationsTYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. […]
On the market
- Earliest approval on file
- April 28, 2017
- Generic labelers
- none listed
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the baclofen record
Baclofen (Gablofen) · label of August 12, 2024
Used for
From the label: indicationsBaclofen tablets USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. […]
On the market
- Earliest approval on file
- November 22, 1977
- Generic labelers
- 55 labelers
- Pharmacy cost
- $0.032 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 3
Source: FDA drug labels via openFDA (Abaloparatide label of August 11, 2026, Baclofen label of August 12, 2024); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do abaloparatide and baclofen differ on the record?
In FDA's classes, abaloparatide is a parathyroid hormone-related peptide analog and baclofen a gamma-aminobutyric acid-ergic agonist.
Generics: abaloparatide none approved; baclofen since 1988 (Drugs@FDA).
| Abaloparatide | Baclofen | |
|---|---|---|
| Labeled for | Osteoporosis | Muscle spasms and spasticity |
| Pharmacologic class | Parathyroid Hormone-Related Peptide Analog | gamma-Aminobutyric Acid-ergic Agonist |
| How it works (label) | Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. | n/a |
| Half-life (label) | n/a | n/a |
| Earliest approval on file (Drugs@FDA) | April 28, 2017 | November 22, 1977 |
| First generic approved | none | July 21, 1988 |
| Generic labelers (NDC) | none listed | 55 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | n/a | $0.032 per tablet (Baclofen 10 mg tablet) |
| 12-month price change | n/a | -12% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 3 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 29,258 | 88,351 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to abaloparatide
- every medicine labeled for the same conditions